Mirum制药拟以最高8.2亿美元收购蓝鸟治疗公司

Core Viewpoint - Mirum Pharmaceuticals announced the acquisition of Bluebird Bio for up to $820 million, aimed at enhancing its product portfolio with an experimental drug for severe liver disease [1][4]. Group 1: Acquisition Details - The acquisition involves an initial payment of $250 million in cash and $370 million in stock, with potential milestone payments of up to $200 million based on sales [1][4]. - The deal is expected to be completed in the first quarter of 2026 [3][6]. Group 2: Drug Information - Mirum will gain global rights to the monoclonal antibody Brelovitug, which is in clinical trials for chronic delta hepatitis, a rare and rapidly progressing liver disease affecting approximately 230,000 people in the US and Europe [1][4]. - Delta hepatitis is considered the most severe type of viral hepatitis, occurring only in individuals infected with hepatitis B, and can lead to rapid liver damage or liver cancer [1][4]. - Nearly half of diagnosed patients may die from liver-related complications within 10 years [1][4]. - In a mid-stage clinical trial, all patients treated with Brelovitug for 48 weeks showed a decrease in delta hepatitis virus load, with up to 82% of patients normalizing liver enzyme levels [1][4]. Group 3: Funding and Future Plans - Mirum has raised $200 million through a targeted equity offering to healthcare investors to support the drug's further development and commercialization [2][5]. - The drug is currently in late-stage clinical trials, with results expected in the second half of 2026, and Mirum plans to apply for US regulatory approval in 2027 if trials are successful [2][5].